poisar

Stocks · News reference

BioMarin Submits Regulatory Filings for Vosoritida in Hypochondroplasia

Fiscal.ai

BioMarin has submitted applications to the FDA and EMA to expand the therapeutic indication of its drug vosoritida to include the treatment of hypochondroplasia.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading